Valbiotis SAS (ALVAL) - Net Assets
Based on the latest financial reports, Valbiotis SAS (ALVAL) has net assets worth €11.75 Million EUR (≈ $13.74 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€19.89 Million ≈ $23.26 Million USD) and total liabilities (€8.14 Million ≈ $9.52 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ALVAL financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €11.75 Million |
| % of Total Assets | 59.06% |
| Annual Growth Rate | 71.66% |
| 5-Year Change | 46.59% |
| 10-Year Change | N/A |
| Growth Volatility | 825.42 |
Valbiotis SAS - Net Assets Trend (2015–2024)
This chart illustrates how Valbiotis SAS's net assets have evolved over time, based on quarterly financial data. Also explore how large is Valbiotis SAS's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Valbiotis SAS (2015–2024)
The table below shows the annual net assets of Valbiotis SAS from 2015 to 2024. For live valuation and market cap data, see Valbiotis SAS market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €10.37 Million ≈ $12.12 Million |
-47.10% |
| 2023-12-31 | €19.60 Million ≈ $22.91 Million |
+47.22% |
| 2022-12-31 | €13.31 Million ≈ $15.56 Million |
-6.45% |
| 2021-12-31 | €14.23 Million ≈ $16.64 Million |
+101.20% |
| 2020-12-31 | €7.07 Million ≈ $8.27 Million |
-13.84% |
| 2019-12-31 | €8.21 Million ≈ $9.60 Million |
+10.80% |
| 2018-12-31 | €7.41 Million ≈ $8.66 Million |
-27.07% |
| 2017-12-31 | €10.16 Million ≈ $11.88 Million |
+2653.12% |
| 2016-12-31 | €369.00K ≈ $431.40K |
+361.25% |
| 2015-12-31 | €80.00K ≈ $93.53K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Valbiotis SAS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 928600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €1.58 Million | 15.23% |
| Other Comprehensive Income | €17.56 Million | 169.37% |
| Other Components | €1.25 Million | 12.09% |
| Total Equity | €10.37 Million | 100.00% |
Valbiotis SAS Competitors by Market Cap
The table below lists competitors of Valbiotis SAS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Powercom Co Ltd
TW:3043
|
$25.17 Million |
|
Sakthi Sugars Limited
NSE:SAKHTISUG
|
$25.19 Million |
|
Nova EYE Medical Ltd
AU:EYE
|
$25.19 Million |
|
Delignit AG
XETRA:DLX
|
$25.20 Million |
|
Step One Clothing Ltd
AU:STP
|
$25.17 Million |
|
Firebird Metals Ltd
AU:FRB
|
$25.16 Million |
|
LQwD FinTech Corp
V:LQWD
|
$25.15 Million |
|
Inventec Besta Co Ltd
TW:8201
|
$25.15 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Valbiotis SAS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 19,600,000 to 10,368,000, a change of -9,232,000 (-47.1%).
- Net loss of 10,025,000 reduced equity.
- Other comprehensive income increased equity by 10,404,000.
- Other factors decreased equity by 9,611,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-10.03 Million | -96.69% |
| Other Comprehensive Income | €10.40 Million | +100.35% |
| Other Changes | €-9.61 Million | -92.7% |
| Total Change | €- | -47.10% |
Book Value vs Market Value Analysis
This analysis compares Valbiotis SAS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.41x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.14x to 1.41x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | €6.49 | €0.93 | x |
| 2016-12-31 | €0.10 | €0.93 | x |
| 2017-12-31 | €3.84 | €0.93 | x |
| 2018-12-31 | €1.97 | €0.93 | x |
| 2019-12-31 | €1.75 | €0.93 | x |
| 2020-12-31 | €0.96 | €0.93 | x |
| 2021-12-31 | €1.55 | €0.93 | x |
| 2022-12-31 | €1.32 | €0.93 | x |
| 2023-12-31 | €1.57 | €0.93 | x |
| 2024-12-31 | €0.66 | €0.93 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Valbiotis SAS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -96.69%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5728.57%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.89x
- Recent ROE (-96.69%) is above the historical average (-159.60%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -935.44% | -7390.00% | 0.01x | 14.67x | €-746.90K |
| 2016 | -161.14% | -91.80% | 0.40x | 4.41x | €-629.80K |
| 2017 | -24.05% | -81433.33% | 0.00x | 1.25x | €-3.46 Million |
| 2018 | -67.04% | -6287.34% | 0.01x | 1.61x | €-5.71 Million |
| 2019 | -67.05% | -6048.35% | 0.01x | 1.83x | €-6.32 Million |
| 2020 | -53.54% | -123.84% | 0.15x | 2.94x | €-4.54 Million |
| 2021 | -61.00% | -2913.09% | 0.01x | 2.00x | €-10.10 Million |
| 2022 | -92.48% | -1568.41% | 0.03x | 2.04x | €-13.64 Million |
| 2023 | -37.59% | -155.67% | 0.14x | 1.70x | €-9.33 Million |
| 2024 | -96.69% | -5728.57% | 0.01x | 1.89x | €-11.06 Million |
Industry Comparison
This section compares Valbiotis SAS's net assets metrics with peer companies in the Packaged Foods industry.
Industry Context
- Industry: Packaged Foods
- Average net assets among peers: $1,552,064,020
- Average return on equity (ROE) among peers: -117.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Valbiotis SAS (ALVAL) | €11.75 Million | -935.44% | 0.69x | $25.17 Million |
| Fleury Michon (ALFLE) | $221.72 Million | 7.58% | 1.78x | $101.35 Million |
| Sapmer (ALMER) | $29.00 Million | 3.77% | 2.04x | $32.00 Million |
| Paulic Meunerie Sa (ALPAU) | $1.59 Million | 10.03% | 3.96x | $6.83 Million |
| Poulaillon SA (ALPOU) | $24.32 Million | 6.61% | 1.81x | $31.94 Million |
| Rapid Nutrition PLC (ALRPD) | $180.38K | -1117.30% | 4.09x | $4.94 Million |
| Danone SA (BN) | $11.74 Billion | 9.53% | 1.70x | $50.25 Billion |
| Bonduelle S.C.A. (BON) | $568.29 Million | 9.44% | 1.91x | $324.25 Million |
| Saint Jean Groupe Société anonyme (SABE) | $62.48K | 2.31% | 0.57x | $67.33 Million |
| Savencia SA (SAVE) | $1.38 Billion | 6.75% | 1.52x | $771.57 Million |
About Valbiotis SAS
Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France. The company offers Lipridrivea for the treatment of hypercholesterolemia. It develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; a… Read more